DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20202939

Comparative efficacy study of brimonidine tartrate 0.15% and timolol maleate 0.5% ophthalmic solution (benzalkonium chloride free) versus Brimolol® (with benzalkonium chloride) following single ocular instillation in New Zealand white rabbits

Amit Thavkar, Sateesh Kumar Chauhan, Subhas Bhowmick, Vinod Burade

Abstract


Background: Benzalkonium chloride (BKC) is the most used preservative in topical eye drops but it causes effects such as dry eye and trabecular meshwork degeneration. Polyhexamethylene biguanide (PHMB) is a polymeric biguanide is a less harmful preservative used in ophthalmic solutions. The objective of this study to com-pare the efficacy of PHMB preserved versus BKC preserved ophthalmic solutions containing brimonidine tartrate and timolol maleate on intraocular pressure (IOP) following single ocular instillation in New Zealand white (NZW) rabbits.

Methods: This study was conducted on 12 normotensive male NZW rabbits (2.9-3.6 kg) between 6-9 months of age. Animals received single ocular instillation of 35 µl ophthalmic solution containing brimonidine tartrate 0.15 %w/v and timolol maleate 0.5% w/v with PHMB as preservative (n=6, test) or BKC as preservative (n=6, reference) as per the randomization. Intraocular pressure (IOP) was measured before and 2, 4, 6, 8 and 24 hours after instillation using a pneumatonometer. Percentage change in IOP from pre-instillation values were calculated. Changes in IOP were analysed using the repeated-measures analysis of variance followed by Bonferroni post-test.

Results: Single ocular instillation of PHMB and BKC formulations show significant IOP reduction up to 6 hours as compared with baseline (p<0.05). Reduction in IOP was 35.8% and 32.0% at 2 hours with PHMB and BKC formulations respectively. No differences were observed between the test and reference groups for change in IOP from baseline.

Conclusions: PHMB preserved brimonidine tartrate 0.15% w/v and timolol maleate 0.5% w/v ophthalmic solution was comparable to BKC preserved solution in normotensive NZW rabbits.


Keywords


Polyhexamethylene biguanide, Ophthalmic solution, Intraocular pressure, Brimonidine, Timolol

Full Text:

PDF

References


Jean DSM, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Am J Ophthalmol. 2000;130(2):264-5.

Messmer EM. Preservatives in ophthalmology. Ophthalmologe. 2012;109(11):1064-70.

Coroi MC, Bungau S, Tit M. Preservatives from the eye drops and the ocular surface. Rom J Ophthalmol. 2015;59(1):2-5.

Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131-5.

Duru Z, Ozsaygili C. Preservative-free versus preserved brimonidine 0.15% preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. Cutan Ocul Toxicol. 2019;27:1-4.

Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol. 2005;99:703-15.

Romanowski EG, Yates KA, Connor OKE, Mah FS, Shanks RM, Kowalski RP. Evaluation of polyhexamethylene biguanide (PHMB) as a disinfectant for adenovirus. JAMA Ophthalmol. 2013;131:495-8.

Napavichayanun S, Amornsudthiwat P, Pienpinijtham P, Aramwit P. Interaction and effectiveness of anti-microbials along with healing-promoting agents in a novel bio-cellulose wound dressing. Mater Sci Eng C Mater Biol Appl. 2015;55:95-104.

Polihexanide KK. A safe and highly effective biocide. Skin Pharmacol Physiol. 2010;23:7-16.

Mueller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother. 2008;61:1281-7.

Konetzka WA, Pelczar MJ, Gottlieb S. Chemical Sterilization Techniques. J Hyg Sci. 2013;6(4):2-5.

Greig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging. 2015;32(3):251-60.

Eberlein T, Haemmerle G, Signer M, Gruber Moesenbacher U, Traber J, et al. Comparison of PHMB-containing dressing and silver dressings in patients with critically colonised or locally infected wounds. J Wound Care. 2012;21(1):18-20.

To E, Dyck R, Gerber S, Kadavil S, Woo KY. The Effectiveness of Topical Polyhexamethylene Biguanide (PHMB) Agents for the Treatment of Chronic Wounds: A Systematic Review. Surg Technol Int. 2016;29:45-51.

Lerner SF, Oddone F, Lu DW, Sanseau A, Guarro M, Ridolfi A, et al. Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations in Glaucoma and Ocular Hypertension. Clin Ophthalmol. 2019;13:2411-9.

Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha-2 adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997;6(4):250-8.

Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(1):9-18.

Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514-7.

Wang Z, Denys I, Chen F, Cai L, Wang X, Daniel R, et al. Complete atrioventricular block due to timolol eye drops: a case report and literature review. BMC Pharmacol Toxicol. 2019;20:73.

Hurlow J. The benefits of using polyhexamethylene biguanide in wound care. Br J Community Nurs. 2017;3:16-8.

Trapero MC, Torrijos MM, Conde FL, Torrijos TM, Martin ME, Cerro PJL, et al. Surgical site infections. Effectiveness of polyhexamethylene biguanide wound dressings. Enferm Clin. 2013;23(2):56-61.

Zhang R, Park M, Richardson A, Tedla N, Pandzic E, Paiva CS, et al. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. Ocul Surf. 2019;pii:S1542-0124(19)30285.

Larkin DF, Kilvington S, Dart JK. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992;99(2):185-91.